Tc-99m Tilmanocept for Sentinel Node Mapping

Q: Does tilmanocept involve more radiation risk than other Tc-99m agents?

No. Tilmanocept is a Tc-99m agent used at low administered activity for lymphatic mapping, so patient and staff dose are governed by the same Tc-99m physics, time-distance-shielding practices, and 10 CFR Part 20 limits as other diagnostic Tc-99m procedures.

Technetium-99m tilmanocept (Lymphoseek) is a receptor-targeted sentinel-node imaging agent: instead of being mechanically trapped like a colloid, it binds the CD206 mannose receptor on reticuloendothelial cells inside the lymph node. Its small synthetic backbone — a dextran core carrying mannose and DTPA groups, about 7.1 nm in diameter — clears quickly from the injection site and stays out of downstream nodes, which helps the surgeon and nuclear medicine physician identify the true sentinel node rather than every node in the chain.¹² That molecular design, the technetium-99m physics behind same-day and next-day dosing, and the radiation-safety context are what this guide connects.

Introduction

Sentinel lymph node biopsy lets a surgeon sample the first node draining a tumor to decide whether a full nodal dissection is needed. For decades the radiotracer of choice was a filtered Tc-99m sulfur colloid, which maps lymphatics because colloid particles are physically retained in the node. Colloids work, but they are imperfect: particle size is polydisperse, injection-site clearance is slow, and the tracer can migrate to second- and third-echelon nodes, blurring the distinction between the sentinel node and its neighbors.¹

Tilmanocept was engineered from the receptor up to fix those limitations. It is the first of a class of diagnostic agents built on a macromolecular backbone with a defined number of attachment sites for a receptor substrate (mannose) and an imaging reporter (Tc-99m via DTPA).¹ For a medical physicist supporting a nuclear medicine or surgical program, the agent is a useful case study in how molecular design, radionuclide physics, and radiation-safety practice meet in one procedure. For the broader procedure context, see our overview of lymphoscintigraphy and sentinel-node mapping.

Topic Explanation

What tilmanocept is

Tilmanocept is a synthetic macromolecule — diethylenetriaminepentaacetic acid (DTPA)–mannosyl–dextran — labeled with technetium-99m for lymphatic mapping and sentinel node localization. The original design work by Vera and colleagues built the molecule by attaching amine leashes to a dextran backbone, then conjugating DTPA (to chelate Tc-99m) and mannose (the receptor substrate). The reported construct had a molecular weight of about 35,800 g/mol and a hydrodynamic diameter of about 7.1 nm, with roughly 8 DTPA and 55 mannose groups per dextran molecule.¹

The agent is supplied as a non-radioactive kit that the radiopharmacy reconstitutes with Tc-99m sodium pertechnetate, giving labeling yields in excess of 98%.¹ It was approved by the U.S. Food and Drug Administration for lymphatic mapping with a hand-held gamma counter to locate lymph nodes draining a primary tumor, and for guiding sentinel node biopsy in breast cancer, melanoma, and clinically node-negative squamous cell carcinoma of the oral cavity, among other solid tumors.²⁴

How it maps the sentinel node

Two mechanisms distinguish tilmanocept from a colloid:

Small size → fast transit. Because tilmanocept is a small, defined molecule rather than a large particle, it leaves the interstitial injection site quickly and enters the lymphatics rapidly. In the preclinical model, injection-site clearance was significantly faster than filtered Tc-99m sulfur colloid.¹
Receptor binding → retention in the sentinel node, not downstream. The mannose groups bind to the CD206 mannose-binding receptor expressed on macrophages and dendritic cells in the node. This receptor binding anchors the tracer in the first node it reaches and limits passage to second-echelon nodes.¹³

The combination — rapid departure from the injection site plus receptor-mediated capture in the first node — is what gives tilmanocept its characteristic profile of high sentinel-node extraction with low distal-node accumulation.¹³

Key Technical Principles

Receptor-targeted vs colloidal mapping

Property	Tc-99m tilmanocept	Filtered Tc-99m sulfur colloid
Mapping mechanism	CD206 mannose-receptor binding	mechanical trapping of colloid particles
Effective size	~7.1 nm molecule (defined)	polydisperse particles, larger and variable
Injection-site clearance	rapid	slower
Second-echelon (distal) node uptake	low	higher
Receptor affinity ( $K_{d}$ )	~0.12 nmol/L	not applicable
Node extraction (preclinical popliteal)	~90–98%	~67–79%

The receptor affinity is extraordinarily high: Vera and colleagues reported an equilibrium dissociation constant $K_{d} \approx 0.12$ nmol/L for binding to the mannose-terminated receptor, which is why the tracer stays put once it reaches a receptor-bearing node.¹ The low distal-node uptake is the practically important consequence: a cleaner single-node signal reduces the chance of excising extra nodes.

The chemistry is about molecules, not millicuries

A useful sense of scale: the labeled dose carries only a tiny molar amount of tilmanocept. A 50 µg dose of a 35,800 g/mol molecule is

n = \frac{50 \times 1 0 ^{- 6} g}{35 , 800 g/mol} \approx 1.4 \times 1 0^{- 9} mol = 1.4 nmol

That nanomolar quantity is enough because the receptor affinity is sub-nanomolar and each dextran carries dozens of mannose groups for multivalent binding.¹ The imaging signal, by contrast, comes entirely from the Tc-99m attached through DTPA — the molecule is the vehicle, the technetium is the beacon.

Technetium-99m decay and the same-day / next-day choice

Technetium-99m decays by isomeric transition with a physical half-life of about 6.0 hours, emitting a 140 keV gamma that both the gamma camera and the intraoperative probe detect.⁸ Its decay follows

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{6.0 h} \approx 0.116 h^{- 1}

This is the arithmetic behind the two dosing regimens. For a same-day procedure, the U.S. label recommends 18.5 MBq (0.5 mCi) given at least 15 minutes before mapping, with the procedure completed within 15 hours.⁴ For a next-day procedure the injected activity is increased to compensate for overnight decay. Over an injection-to-surgery interval of, say, 12 hours the surviving fraction is

\frac{A ( 12 )}{A _{0}} = e^{- (0.116) (12)} = e^{- 1.39} \approx 0.25

so only about one-quarter of the activity remains; at 15 hours the fraction is about $e^{- 1.73} \approx 0.18$ , roughly one-sixth. That is why next-day protocols administer on the order of 74 MBq — about four times the same-day activity — so that adequate counts remain in the sentinel node at the time of surgery.⁴ The same-day/next-day decision is therefore a straightforward decay-correction problem, and the physicist's job is to confirm that the counts expected at surgery clear the probe's detection threshold with margin.

Quality control touchpoints

Because the activity is delivered to the operating room and used with an intraoperative probe, several QC chains converge:

Dose calibrator. Every dose is assayed before administration; the dose calibrator must pass constancy, accuracy, linearity, and geometry checks.
Radiochemical purity. Labeling yield and radiochemical purity are confirmed per the package insert, using the facility's thin-layer chromatography radiochemical-purity method.
Intraoperative gamma probe. Sensitivity, energy windowing, and shielding/collimation are verified so the probe reliably finds a node whose counts have decayed overnight; see intraoperative gamma probe QC.

Clinical Impact

Diagnostic performance

Tilmanocept has been evaluated in phase III trials across tumor types. In a multi-institutional phase III trial in intraoral and cutaneous head-and-neck squamous cell carcinoma, patients received 50 µg of tilmanocept labeled with either 0.5 mCi (same day) or 2.0 mCi (next day); the agent identified at least one sentinel node in 97.6% of patients, with a false-negative rate of 2.56%, a negative predictive value of 97.8%, and overall accuracy of 98.8% relative to elective neck dissection, and no significant difference between same-day and next-day procedures.³ Reviews across breast cancer and melanoma similarly report high identification rates and the practical advantages of rapid injection-site clearance and low distal-node accumulation.²⁵

Why the physics helps the surgeon

The receptor-targeted profile is not just elegant chemistry — it changes the intraoperative experience. Low second-echelon uptake means fewer "hot" nodes that are not truly sentinel, and fast injection-site clearance reduces the "shine-through" background that can swamp a nearby node (a well-known difficulty for axillary nodes close to a breast injection site).¹² A cleaner count profile at the probe is a direct, physical benefit of the molecule's size and binding.

Practical Optimization Tips

Pick the regimen from the schedule, then do the decay math. If surgery is next-day, confirm the injected activity leaves adequate node counts after the expected interval using $A_{0} e^{- λ t}$ ; do not assume a same-day activity will suffice overnight.⁴
Inject with margin on timing. The label requires at least 15 minutes before mapping and completion within 15 hours for the same-day regimen; build that window into the schedule.⁴
Treat the probe as a QC instrument, not an accessory. Verify probe sensitivity and energy window on a known source before cases, especially for next-day work where node counts are lower.
Coordinate the radiopharmacy and the OR. Assay every dose, document radiochemical purity, and transport under the facility's radiation-safety procedures so the dose arrives in-spec and on time.
Control injection-site contamination. Interstitial injections and any back-flow should be managed with standard contamination-control practice; survey hands, gloves, and the field as applicable.

Regulatory Considerations

Tilmanocept is byproduct material used under a medical-use license, and an injectable prescription radiopharmaceutical regulated by the FDA — so both frameworks apply. The nuclear medicine physics and radiation safety sit under NRC or Agreement State rules; the drug itself sits under FDA labeling.

FDA labeling. The prescribing information defines the approved indications, the recommended activity and timing, reconstitution, and handling.⁴
10 CFR Part 35 (medical use). Use of Tc-99m tilmanocept falls under the medical-use program, including authorized-user requirements, dose-calibrator and survey-instrument checks, and radiation-safety procedures.⁶
10 CFR Part 20 (protection against radiation). Occupational and public dose limits, surveys, and ALARA apply to the preparation, injection, imaging, and operating-room phases.⁷
State and Agreement State programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington DC and Delaware are regulated directly by the NRC for radioactive material. Confirm which authority issues the license and applies the reporting and survey requirements.
Procedure standards. Professional-society procedure guidance for lymphoscintigraphy and sentinel-node localization informs technique and documentation.

Frequently Asked Questions (FAQs)

How is Tc-99m tilmanocept different from Tc-99m sulfur colloid?

Tilmanocept is a receptor-targeted molecule that binds CD206 mannose receptors on reticuloendothelial cells in the node, whereas sulfur colloid is mechanically trapped. Its small 7.1 nm size gives faster injection-site clearance and lower accumulation in second-echelon nodes, which can sharpen identification of the true sentinel node.¹³

What activity of Tc-99m tilmanocept is administered?

In the U.S. label the recommended activity is 18.5 MBq (0.5 mCi) given at least 15 minutes before mapping, with the procedure completed within 15 hours. Protocols using 50 µg of tilmanocept with about 18.5 MBq for same-day surgery or about 74 MBq for next-day surgery reflect the need to offset Tc-99m decay overnight.³⁴

Why does a next-day protocol use more activity than a same-day protocol?

Technetium-99m has a physical half-life of about 6 hours, so over an overnight interval of roughly 12 to 15 hours only about one-quarter to one-sixth of the injected activity remains. Next-day protocols inject more activity so adequate counts remain in the sentinel node at surgery.⁴⁸

What quality control applies to Tc-99m tilmanocept?

The kit is reconstituted with Tc-99m pertechnetate and the dose is assayed in a dose calibrator before administration. Radiochemical purity is confirmed per the package insert, and the dose calibrator, survey meters, and intraoperative gamma probe are maintained under the facility's routine QC program.⁴

Does tilmanocept involve more radiation risk than other Tc-99m agents?

No. It is a Tc-99m agent used at low administered activity, so patient and staff dose are governed by the same Tc-99m physics, time-distance-shielding practice, and 10 CFR Part 20 limits as other diagnostic Tc-99m procedures.⁷

Who supports a sentinel-node program from the physics side?

A board-certified medical physicist and the radiation safety officer support dose-calibrator and gamma-probe QC, radiation-safety procedures for injection and the operating room, and the license and training requirements under 10 CFR Part 35 and the applicable state program.⁶

Key Takeaways

Tilmanocept maps sentinel nodes by CD206 receptor binding, not colloidal trapping; its ~7.1 nm mannosyl-dextran design gives fast injection-site clearance and low distal-node uptake.¹
Receptor affinity is sub-nanomolar ( $K_{d} \approx 0.12$ nmol/L), so a nanomolar molar dose (≈1.4 nmol in 50 µg) is enough; the Tc-99m supplies the signal.¹
Same-day vs next-day activity is a decay-correction decision: with $T_{1/2} \approx 6$ h, ~12–15 h leaves roughly one-quarter to one-sixth of the activity, so next-day protocols use about 4× the same-day activity.⁴⁸
Phase III data show high identification rates and low false-negative rates, with same-day and next-day performance comparable.³
QC spans the dose calibrator, radiochemical purity, and the intraoperative gamma probe; the probe check matters most for low-count next-day cases.
Radiation safety follows standard Tc-99m practice under 10 CFR Parts 20 and 35 (or the Agreement State equivalent), with FDA labeling governing the drug.⁴⁶⁷

Conclusion

Tc-99m tilmanocept shows how a well-chosen molecular design translates into a cleaner clinical signal. By binding a specific receptor rather than relying on particle size, it leaves the injection site quickly and holds in the first node it reaches, giving the surgeon a sharper target and the nuclear medicine team a more predictable count profile. None of that removes the physics the physicist still owns: the technetium-99m half-life sets the dosing math, the dose calibrator and gamma probe set the measurement chain, and 10 CFR Parts 20 and 35 set the safety frame. A program that treats tilmanocept as what it is — a receptor-targeted Tc-99m agent with a decay-driven dosing decision — gets the benefit of the chemistry while keeping the radiation-safety basics firmly in place.

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear medicine and surgical programs with PET/CT and nuclear medicine physics, dose-calibrator and gamma-probe QC, radiation-safety procedures for radiopharmaceutical handling and the operating room, and radiation safety officer support aligned with NRC and Agreement State requirements.

DRPS serves facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Related Resources

References

Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran. Journal of Nuclear Medicine. 2001;42(6):951-959. PubMed
Tausch C, Baege A, Rageth C. Mapping lymph nodes in cancer management — role of (99m)Tc-tilmanocept injection. OncoTargets and Therapy. 2014;7:1151-1158. doi:10.2147/OTT.S50394. PubMed
Agrawal A, Civantos FJ, Brumund KT, et al. [(99m)Tc]Tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck: results of a phase III multi-institutional trial. Annals of Surgical Oncology. 2015;22(11):3708-3715. doi:10.1245/s10434-015-4382-x. PubMed
U.S. Food and Drug Administration. Lymphoseek (technetium Tc 99m tilmanocept) prescribing information. 2013. accessdata.fda.gov
Surasi DS, O'Malley J, Bhambhvani P. 99mTc-tilmanocept: a novel molecular agent for lymphatic mapping and sentinel lymph node localization. Journal of Nuclear Medicine Technology. 2015;43(2):87-91. doi:10.2967/jnmt.115.155960. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
National Institute of Standards and Technology / National Nuclear Data Center. Technetium-99m decay data (half-life ≈ 6.0 h; 140.5 keV gamma). nndc.bnl.gov